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The Authors Reply: We thank Pliquett et al.1 for their interest
in our article.2 Contrary to what is suggested in their title, we
did not investigate hemodialysis and peritoneal dialysis (PD)
outcomes in patients with chronic heart disease, but we com-
pared survival by dialysis modality in incident end-stage renal
disease patients with congestive heart failure (CHF).2
As they point out,1 our study is observational by nature.
Limitations of such studies, including CHF diagnosis, New York
Heart Association (NYHA) class diagnosis, and nonavailability of
surrogates of CHF, were discussed in the paper.2 Unfortunately,
the cause of CHF is not available in the REIN Registry.
Reliability of CHF diagnosis is based on quality control
procedures and on our validation study.2 Echocardiographic
or biological markers could not be surrogates of CHF in the
absence of validated criteria for diagnosis.3 The use of data
after dialysis initiation, as hydration level, would have led to a
selection bias because they depend on dialysis modality.4
The REIN Registry does not differentiate NYHA stages III
and IV. However, we can hypothesize that the majority of patients
with glomerular ﬁltration rate X15ml/min per 1.73m2 had
NYHA IV CHF. In this group, PD mortality remained higher.2
Epidemiological studies aim to generate hypotheses and
improve previous reports. Only a randomized trial could ensure
the veracity of survival comparison by dialysis modality.
Waiting for further evidence, dialysis modality choice
should take into account quality of life, patient’s preferences,
and economic data. It seems reasonable to advise nephrologists
to pay particular attention to CHF patients on PD.
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Red blood cell life span and
‘erythropoietin resistance’
To the Editor: We read with interest Bamgbola’s review on
erythropoietin (EPO) resistance in a recent issue of the Journal.1
Although the author presents a wide range of mechanisms
and conditions associated with EPO resistance (including
‘accelerated turnover rate of red cells’), the integral role of red
blood cell (RBC) life span deserved more explicit elaboration,
in our opinion. The response to EPO, meaning the hemoglo-
bin (Hgb) concentration achieved with a certain EPO regimen,
is really a continuum rather than a binary outcome, and RBC
life span (RBCLS) is a basic component of the process.2,3
Reduction in RBCLS will necessarily entail a reduction in Hgb
unless compensated for by increased RBC production rate
(in dialysis patients primarily mediated by EPO and iron
therapy). When RBC production cannot increase materially,
regardless of increases in EPO dose, a short RBCLS becomes
the limiting factor in Hgb increase, giving the impression of
resistance to EPO.
We have determined RBCLS repeatedly in 44 hemodialysis
(HD) patients by carbon monoxide measurements4 and saw
an average baseline RBCLS of 70±23 days, which is in keeping
with literature data. It is noteworthy that only one of these
patients met the criteria of EPO resistance cited by Bamgbola,
illustrating how rarely this deﬁnition is met. During this
period, RBCLS was measured twice in this patient (spaced one
month apart) and was found to be 35.9 days and 39.4 days,
respectively (Figure 1). Diagnostic workup according to the
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Figure 1 |Time course of epoetin alfa dose, hemoglobin
concentration, and red blood cell life span (RBCLS) in a
patient with ‘EPO resistance’. EPO, erythropoietin.
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ﬂowchart in Figure 3 of Bamgbola’s review revealed none of
the suggested etiologies.
As shown by our data and that of others, HD patients
exhibit a wide range of RBCLS, with almost one in six patients
having an RBCLS below 47 days. RBCLS and EPO respon-
siveness are closely related—a fact that is often neglected or
underappreciated in clinical practice. A consideration of
RBCLS is vital for interpretation of EPO responsiveness,
particularly in populations with notably variable RBCLS, such
as dialysis patients.
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The Author Replies: I read with utmost interest the cor-
respondence posted by Yanna et al.1 in the Journal in response
to the review article on erythropoietin (EPO) resistance2 that
was published on 22 June 2011. Although I strongly identify
with the premise for the argument, I disagree with the
syllogistic connotation. Indeed, the apparent lack of explicit
elaboration on red cell survival as a topic is not due to its lack
of importance but rather borne out of the near-universality of
its role in anemia.
Practically all of the etiological factors discussed in the
article are mediated by at least one of these three pathophys-
iological processes: (1) inadequate hematopoiesis; (2) shorter
life span of red cells; and (3) blood loss.2 Often, these functional
disturbances are not mutually exclusive but are rather intrin-
sically integrated. For example, pathway B, which is the bone
of contention, is involved in a majority of the highlighted risk
factors. Hence, all of the hemolytic conditions, oxidative
diseases, nutritional deﬁciencies, malignancies, viral infections,
and hyperparathyroidism, are partly mediated by a shorter
red cell survival (see Table 1).2
I am not surprised that most of the subjects in the study
reported by the authors failed to meet the criteria for EPO
resistance.3 The study group is selective, excluding patients
with pathologies that are likely to cause EPO-resistant anemia
as deﬁned.2,3 To enhance its predictive value, the deﬁnition
was deliberately restrictive. If we use red cell survival as a
criterion, depending on the cutoff values, no doubt the
majority of renal patients with end stage kidney disease will
be deemed EPO resistant.3,4 Moreover, as indicated in
the article, application of this deﬁnition must take cognizance
of the demographic and clinical variables of the study
population.2
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Table 1 | Etiological factors of erythropoietin resistance that are mediated by poor erythrocyte survival
Poor erythrocyte survival
Clinical entities Highly likely Less likely Least likely
Hemolysis: AIHA, HUS, G6PD, HbS, sepsis, hypersplenism +
Oxidative stress: surgery, HD +
Viral infections: AIDS, CMV, EBV, hepatitis ± ± ±
Malignancy +
Drugs: chemotherapy, ISA +
Fe, folate, vit B12, vit C, vit E, carnitine, and Cu deficiency ± ±
Alcoholism +
Heavy metal toxicity: aluminum, lead +
Pro-inflammatory: poor dialysis, HD, SLE, failed transplant ± +
Hyperparathyroidism +
Abbreviations: þ , yes;±, yes, effect varies with clinical entities; AIDS, acquired immunodeficiency syndrome; AIHA, autoimmune hemolytic anemia; CMV, cytomegalovirus;
Cu, copper; Fe, iron; folate, folic acid; G6PD, glucose 6nn-phosphate dehydrogenase deficiency; HbS, hemoglobin S; HD, hemodialysis; HPTH, hyperparathyroidism;
HUS, hemolytic uremia syndrome; ISA, immunosuppressive agents; SLE, systemic lupus erythematosus; vit, vitamin.
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